Avn-C:Improves memory and cognitive functions in the transgenic mouse models of AD.Reverses the impaired LTP in both ex vivo- and in vivo-treated AD mice hippocampus.Improves recognition and spatial memory.Reduces caspase-3 cleavage.Reverses neuroinflammation.Increases levels of phosphorylated glycogen synthase kinase-3β (pS9GSK-3β) and IL-10. These beneficial effects are mediated through the binding of Avn-C to α1A adrenergic receptors, stimulating AMPK. The gene discussed is IL10; the disease is Alzheimer disease.